Hydantoin MMP-12 Inhibitors With Heteroaryl Specificity Tuning
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing hydantoin derivatives used as MMP-12 inhibitors lack specificity and potency, necessitating the development of compounds with improved pharmacological properties.
Innovation Solution
Hydantoin derivatives with specific structural modifications, such as varying ring A to a 5- to 6-membered monocyclic heteroaryl and substituting R2 with groups like —CH3, —C(O)NH2, —CH2OH, or —OCH3, enhance MMP-12 inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing hydantoin derivatives are used as MMP-12 inhibitors, then some inhibition activity is achieved, but specificity and potency are insufficient
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups at defined positions on the heteroaryl ring (positions 2, 4, or 6) of the hydantoin derivative. These localized modifications with specific chemical groups (halo, alkyl, alkoxy, amino, carboxy, etc.) enhance the compound's specificity for MMP-12 while maintaining inhibition activity, resolving the contradiction between specificity and versatility.
Solution Approach 2:
The patent employs parameter changes by systematically varying the heteroaryl ring structure (5- to 6-membered rings), substituent types, and their positions to optimize both specificity and potency. This structured modification of chemical parameters enables the compounds to achieve high MMP-12 specificity while retaining broad applicability across multiple diseases mediated by MMP-12.
2Reliability
If hydantoin derivatives with specific structural modifications are developed, then potency and specificity are improved, but compound complexity increases
Solution Approach 1:
The patent achieves universality by designing a core hydantoin-heteroaryl scaffold that maintains consistent potency and specificity improvements across multiple disease indications (emphysema, asthma, fibrosis, cancer, etc.). This universal structure-activity relationship allows the modified compounds to function effectively across diverse pathological conditions without requiring further structural complexity.
Data Source
AI summary
Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.